In this enlightening episode, Anthony and Bernie chat about FLT3+ AML with Dr. Dale Bixby, Clinical Professor and expert in leukemia at the University of Michigan. We use two clinical cases to take a deep dive into the biology and prognostic implications of FLT3+ AML, pitfalls and controversies of variant allele frequency and allelic ratio testing, and the data that informs the use of FLT3 inhibitors in AML. Watch out for some possibly heretical views!
REFERENCES
Schlenk and Dohner (Impact of AML prognostic markers)l: https://pubmed.ncbi.nlm.nih.gov/19468271/
RATIFY Trial: https://www.nejm.org/doi/full/10.1056/nejmoa1614359
QUANTUM-FIRST: https://library.ehaweb.org/eha/2022/eha2022-congress/356965/harry.erba.quizartinib.prolonged.survival.vs.placebo.plus.intensive.induction.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2233%2Amarker%3D1749%2Afeatured%3D17676
ODAC Review of Quantum-R (quizartinib): https://www.fda.gov/media/124896/download
ELN 2022: https://pubmed.ncbi.nlm.nih.gov/35797463/
WHO Myeloid 2022: https://pubmed.ncbi.nlm.nih.gov/35732831/
Sorafenib Maintenance (RCT China): https://pubmed.ncbi.nlm.nih.gov/32791048/
SorMAIN: https://pubmed.ncbi.nlm.nih.gov/32673171/
RADIUS (midostaurin maintenance): https://pubmed.ncbi.nlm.nih.gov/33288862/
LACEWING Trial: https://pubmed.ncbi.nlm.nih.gov/35917453/
HMA/Ven pooled FLT3: https://pubmed.ncbi.nlm.nih.gov/35063965/
Ven/Aza/Gilteritinib ASH 2022: https://ash.confex.com/ash/2022/webprogram/Paper157210.html
UK NCRI AML 17 Flt3 analysis: https://pubmed.ncbi.nlm.nih.gov/27268085/